M. Capone

发表

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

G. Botti, P. Ascierto, R. Franco, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents

G. Madonna, P. Ascierto, E. Simeone, 2022, Journal for ImmunoTherapy of Cancer.

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

G. Botti, P. Ascierto, V. de Giorgi, 2013, Journal of Translational Medicine.

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

F. Marincola, G. Botti, P. Ascierto, 2013, Journal of Translational Medicine.

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

G. Madonna, D. Mallardo, P. Ascierto, 2018, Journal of Immunotherapy for Cancer.

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

D. Schadendorf, B. Schilling, G. Madonna, 2016, Clinical Cancer Research.

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

G. Madonna, D. Mallardo, P. Ascierto, 2021, Cancers.

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

G. Madonna, D. Mallardo, P. Ascierto, 2017, Journal of Translational Medicine.

Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma

D. Cacchiarelli, G. Madonna, P. Ascierto, 2021, International journal of molecular sciences.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients

G. Madonna, D. Mallardo, P. Ascierto, 2017, Oncoimmunology.

Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment.

G. Madonna, D. Mallardo, G. Botti, 2020, Methods in enzymology.

NEMO-binding domain peptide inhibits proliferation of human melanoma cells.

P. Ascierto, G. Palmieri, A. Ianaro, 2009, Cancer letters.

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

G. Madonna, P. Ascierto, D. Galati, 2020, Journal of Translational Medicine.

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

G. Madonna, D. Mallardo, P. Ascierto, 2019, Journal of Immunotherapy for Cancer.

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients

G. Madonna, P. Ascierto, F. De Galitiis, 2021, Scientific Reports.

PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab

G. Madonna, D. Mallardo, P. Ascierto, 2022, Frontiers in Immunology.

24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome

G. Madonna, D. Mallardo, P. Ascierto, 2021, Journal for ImmunoTherapy of Cancer.

Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave

G. Madonna, G. Botti, P. Ascierto, 2021, Journal of translational medicine.

Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma.

G. Madonna, P. Ascierto, G. Ciliberto, 2022, Cell reports.

Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma

L. Fattore, R. Mancini, G. Madonna, 2022, Theranostics.

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin

L. Fattore, R. Mancini, D. Malpicci, 2019, Cancers.

The Ratio of GrzB+ − FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma

G. Madonna, D. Mallardo, G. Botti, 2021, Cancers.

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

D. Schadendorf, B. Schilling, P. Ascierto, 2016, Clinical Cancer Research.

Molecular Pathogenesis of Melanoma: Established and Novel Pathways

P. Ascierto, G. Palmieri, M. Murphy, 2012 .

Main roads to melanoma

P. Ascierto, G. Palmieri, D. Stroncek, 2009, Journal of Translational Medicine.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Characterization of a Novel Polymorphism in PPARG Regulatory Region Associated with Type 2 Diabetes and Diabetic Retinopathy in Italy

A. Ciccodicola, A. Casamassimi, D. Giugliano, 2008, Journal of biomedicine & biotechnology.

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

G. Botti, P. Ascierto, I. Stanganelli, 2015, Journal of Translational Medicine.

229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy

D. Mallardo, P. Ascierto, J. Vowinckel, 2020, Journal for ImmunoTherapy of Cancer.

Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.

F. Marincola, G. Botti, P. Ascierto, 2015, Cancer letters.

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma

G. Madonna, G. Botti, P. Ascierto, 2019, Scientific Reports.

Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors

G. Viglietto, G. Madonna, D. Mallardo, 2022, Frontiers in Immunology.

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

F. M. Marincola, F. Marincola, G. Botti, 2016, Journal of Translational Medicine.

Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes’ iTNF-α Expression

G. Madonna, P. Ascierto, F. Perna, 2021, Biology.

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

D. Schadendorf, G. Madonna, D. Mallardo, 2020, Journal for ImmunoTherapy of Cancer.

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment

F. Marincola, P. Ascierto, J. Kirkwood, 2010, Journal of Translational Medicine.

Discrepant alterations in main candidate genes among multiple primary melanomas

Susanna Rossari, Daniela Massi, Vincenzo De Giorgi, 2014, Journal of Translational Medicine.

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

G. Madonna, D. Mallardo, P. Ascierto, 2017, Journal of Translational Medicine.

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

P. Ascierto, M. Pistillo, E. Simeone, 2018, Cancer Immunology, Immunotherapy.

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study

P. Ascierto, M. Pistillo, E. Simeone, 2017, Front. Immunol..

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

G. Madonna, P. Ascierto, G. Ciliberto, 2015, Oncoimmunology.

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

M. Todaro, G. Madonna, D. Mallardo, 2019, Cancer Immunology Research.

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

P. Ascierto, G. Ferrara, K. Peris, 2023, Frontiers in Oncology.

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab

Gerardo Botti, Mariaelena Capone, Carmen Ballesteros-Merino, 2017, Oncoimmunology.

A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma

R. Sullivan, P. Ascierto, R. Halaban, 2017, Cancer Immunology Research.

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

K. Flaherty, G. Madonna, D. Mallardo, 2021, Journal of translational medicine.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

D. Schadendorf, S. Ugurel, B. Becher, 2023, Med.

Enzyme activity of circulating CD73 in human serum.

G. Madonna, P. Ascierto, M. Capone, 2019, Methods in enzymology.

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

D. Schadendorf, B. Schilling, P. Ascierto, 2016, European journal of cancer.

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

G. Botti, P. Ascierto, I. Stanganelli, 2015, Journal of Translational Medicine.

New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer

G. Madonna, P. Ascierto, S. Costantini, 2023, International journal of molecular sciences.

Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.

G. Madonna, P. Ascierto, T. Kirchhoff, 2023, European journal of cancer.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

G. Madonna, P. Ascierto, D. Galati, 2020, Journal of Translational Medicine.

Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave

G. Madonna, G. Botti, P. Ascierto, 2021, Journal of translational medicine.

Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps

G. Madonna, P. Ascierto, E. Simeone, 2023, Cancer Immunology, Immunotherapy.

Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients

G. Madonna, D. Mallardo, P. Ascierto, 2023, Journal of Translational Medicine.

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma

Nathalie Harder, Nicolas Brieu, Günter Schmidt, 2019, Scientific Reports.

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab

G. Madonna, D. Mallardo, P. Ascierto, 2023, Journal of Translational Medicine.

Immunoscore: a new possible approach for melanoma classification

Fabrizio Ayala, Gerardo Botti, Mariaelena Capone, 2014, Journal of Immunotherapy for Cancer.

This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. Discrepant alterations in main candidate genes among multiple primary melanomas

G. Botti, P. Ascierto, D. Massi, 2014 .